:: دوره 27، شماره 1 - ( دوماه نامه 1402 ) ::
جلد 27 شماره 1 صفحات 96-90 برگشت به فهرست نسخه ها
ارزیابی عملکرد جنسی در سوء‌مصرف‌کنندگان مواد تحت درمان با متادون و بوپرنورفین در سال 1400
افشین احمدوند ، مطهره منصورنژاد ، زهرا سپهرمنش
واحد توسعه تحقیقات بالینی بیمارستان‌های کارگرنژاد و متینی، دانشگاه علوم‌پزشکی کاشان، کاشان، ایران ، z.sepehrmanesh@gmail.com
چکیده:   (554 مشاهده)
سابقه و هدف: مشکلات عملکرد جنسی از عوارض شایع درمان نگهدارنده متادون و بوپرنورفین است. مطالعه حاضر با هدف ارزیابی عملکرد جنسی مردان معتاد تحت درمان نگهدارنده با متادون و بوپرنورفین انجام شد.
مواد و روش‌ها: در مطالعه مقطعی حاضر 30 مرد تحت درمان نگهدارنده متادون (15 نفر) و بوپرنورفین (15 نفر) از مراکز ترک اعتیاد کاشان وارد مطالعه شدند. برای جمع‌آوری داده‌ها از پرسشنامه وضعیت جنسی گلومبوک - راست استفاده شد. داده‌های جمع‌آوری‌شده ازطریق نرم‌افزار SPSS نسخه 22 ویرایش شدند و با استفاده از آزمون‌های دقیق فیشر، تی مستقل و رگرسیون خطّی مورد تجزیه‌وتحلیل قرار گرفتند.
نتایج: میانگین نمره کلّ وضعیت عملکرد جنسی بین دو گروه متادون (5813/58±38/40) و بوپرنورفین (14/56 ± 38/33) تفاوت معناداری نداشت (0/733= P).
نتیجه‌گیری: نتایج نشان داد که در هر دو گروه، وضعیت عملکرد جنسی، در سطح نامطلوب بوده است؛ بنابراین توصیه می‎شود که مطالعات آتی به ارائه راهکارهایی جهت بهبود عملکرد و رضایت جنسی در بیماران تحت درمان نگهدارنده با متادون و بوپرنورفین متمرکز شوند.
واژه‌های کلیدی: اعتیاد، اختلال عملکرد جنسی، درمان نگهدارنده متادون، درمان نگهدارنده بوپرنورفین
متن کامل [PDF 337 kb]   (299 دریافت)    
نوع مطالعه: پژوهشي | موضوع مقاله: medicine, paraclinic
دریافت: 1401/6/28 | ویرایش نهایی: 1402/5/3 | پذیرش: 1401/11/30 | انتشار: 1402/1/16
فهرست منابع
1. Feng L, Zhang W, Li X. Monitoring of regional drug abuse through wastewater-based epidemiology—A critical review. Sci China Earth Sci 2018; 61(3): 239-55.
2. Aramideh Z, Sahbaeiroy F. Sustained Remission from Drug Addiction among the Attendees of the Meetings of Anonymous Addicts and Rehabilitation Centers in Mashhad, Iran, During 2017. SBRH 2019; 3(2): 378-84.
3. Jamshidi F, Nazari I, Cheraghi M. Risky behaviors of injecting drug users [IDUs) referred to addiction rehabilitation centers in Khuzestan Province in 2014. Online J Health Allied Sci 2017; 16: 5.
4. Rizal MRM, Khan AH, Harun SN, Saleh Z. Gender differences on methadone maintenance treatment outcome among patients with opioid use disorder: A systematic review. J Pharmacy Bioallied Sci 2020; 12(6): 657.
5. Mattick R, Ali R, Lintzeris N. Pharmacotherapies for the treatment of opioid dependence: Efficacy, cost-effectiveness and implementation guidelines: Informa; 1st ed. 2009. 520
6. Jordan CJ, Cao J, Newman AH, Xi ZX. Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine. Neuropharmacology 2019; 158: 107609.
7. Aronson JK. Meyler's side effects of drugs: the international encyclopedia of adverse drug reactions and interactions: Indian J Pharmacol 2016; 48(2): 224.
8. Dhawan A, Modak T, Sarkar S. Transdermal buprenorphine patch: potential for role in management of opioid dependence. Asian J Psychiatr 2019; 40: 88-91
9. Burke NN, Ferdousi M, Deaver DR, Finn DP, Roche M, Kelly JP. Locomotor and anti-immobility effects of buprenorphine in combination with the opioid receptor modulator samidorphan in rats. Neuropharm. 2019; 146: 327-36.
10. Haddadi M, Rahimi-Movaghar A, Farrahi F, Farahmandfar M. Comparison of the effects of methadone with buprenorphine on reproductive [sexual) hormone profile and seminal fluid analysis [fertility) in men on maintenance treatment. Clin Exc 2019; 9(1): 48-60 .[in Persian]
11. Khodabakhsh Nejad F, Moayer F, Khosravi Dehaghi N. Histopathological effect of buprenorphine administration on testis of rat. Pajoohandeh J 2016; 21(3): 130-7. [in Persian]
12. Gowing L, Ali R, White JM, Mbewe D. Buprenorphine for managing opioid withdrawal. Cochrane Database of Systematic Reviews 2017(2).
13. Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor R, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. NIHR Health Technology Assessment programme: Executive Summaries: NIHR J Library; 2007.
14. Mokri A. Methadone, Buprenorhine or Opium Tincture; Choosing the Right Agonist for Maintenance Treatment. J Addiction Med 2014; 1(4): 8-9. [in persian]
15. Massah O. Male Sexual Disorders During Maintenance Therapy; a Comparison Between Methadone and Buprenorphine. Persian J Addiction Med 2015; 2(8): 46-8. [in Persian]
16. Gerra G, Manfredini M, Somaini L, Maremmani I, Leonardi C, Donnini C. Sexualdysfunction in men receiving methadonemaintenance treatment: clinical history and psychobiological correlates. Eur Addict Res 2016; 22(3): 163-75.
17. Bonakdaran S, Akbari Rad M, Hasanzadeh Deloie M, Akhoondpoor Manteghi M, Firoozi A. QTc prolongation in methadone users and its relation with hormonal changes. MUMS 2017; 60(2): 441-9.
18. Yee A, Loh HS, Ng CG. The prevalence of sexual dysfunction among male patients on methadone and buprenorphine treatments: a meta-analysis study. J Sexual Med 2014; 11(1): 22-32.
19. Safarinejad M. Sexual disorders in substance abusers who are treated with methadone.drsafarinejad.net/category/male-uro.
20. Salsitz E. Eiegand T. pharmacotherapy of opioid addiction: putting a real face on a false Demon. J Med Toxicol 2016; 12(1): 58-68.
21. Yee A, Loh HS, Danaee M, Riahi S, Ng CG, Sulaiman AH. Plasma testosterone and sexual function in Southeast Asian men receiving methadone and buprenorphine maintenance treatment. J Sex Me 2018; 15(2): 159-66.
22. Ammozegar FS, Salehi M, Tarrahi MJ, Molaeinezhad M, Moradinasab F. The effect of maintenance treatment with methadone and buprenorphine on sexual function of females addicted to opiates. Iran J Obstet Gynecol Infertil 2021; 24(3): 23-32.
23. Hassanipour Azgomi S, Arab Zozani M, Maghsoudi A, Mokhtari AM, Ghadiri Rad R. Comparing sexual dysfunction in maintenance therapy with Methadone and Buprenorphine in married male. Int J Epidemiol Res 2016; 3(3): 55-65.
24. Quaglio G, Lugoboni F, Pattaro C. Erectile dysfunction in male heroin users, receiving methadone and buprenorphine maintenance treatment. Drug Alcohol Depend 2008; 94(5): 12-8.
25. Kheradmand A, Fazeli A, Meybodi AM. Comparing the effects of methadone, buprenorphine, and opium tincture maintenance therapy on sexual function. Addict Health 2019; 11(2): 120-44.
26. Besharat MA, HOSSEIN ZBR. A comparative study of fertile and infertile women’s mental health and sexual problems. IJPCP 2006; 12(2): 146-53. [in Persian]
27. Besharat MA, Hosseinzadeh Bazargani R, Mirzamani Bafghi M. Sexual problems of infertile couples. Res Behav Sci 2003; 1(2): 8-13.
28. Rust J, Bennun I, Crowe M. The Golombok Rust Inventory of Marital State (GRIMS): Test and handbook. Windsor, United Kingdom: NFER-Nelson. 1988.
29. Yee A, Danaee M, Loh HS, Sulaiman AH, Ng CG. Sexual dysfunction in heroin dependents: a comparison between methadone and buprenorphine maintenance treatment. PloS One 2016; 11(1): e0147852.
30. Tatari F, Farnia V, Faghiyeh Nasiri R, Najafi F. The effects of Trazodone on erectile function in patients on methadone maintenance treatment. Iran J Psychiatry 2010; 5: 164-6.
31. Hosseini SH, Isapour A, Tavakoli M, Taghipour M, Rasuli M. Erectile dysfunction in methadone maintenance patients: a cross sectional study in northern Iran. Iranian J Psychiatr 2013; 8(4): 172-99.
32. Ramdurg S, Ambekar A, Lal R. Sexual dysfunction among male patients receiving buprenorphine and naltrexone maintenance therapy for opioid dependence. J Sex Med 2012; 9(12): 3198-204.
33. Tafreshian S, Javadi M, Fakhraei F, Fatemi SS. Sexual dysfunction in male patients receiving methadone and buprenorphine maintenance treatment in Iran. Heroin Addict Rel Clin Probl 2014; 16(3): 49-54.
34. Wafaee Najjar A, Imamian H, Darabi Z, Kashfi T. Comparison of sexual satisfaction in addicts under maintenance treatment with methadone and buprenorphine. Graduate Students Conference; Mashhad. Mashhad University of Medical Sciences; 2013. [in Persian]
35. Bliesener N, Albrecht S, Schwager A, Weckbecker K, Lichtermann D, Klingmuller D. Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence. J Clin Endocrinol Metabol 2005; 90(1): 203-6.
36. Bawor M, Bami H, Dennis BB, Plater C, Worster A, Varenbut M, et al. Testosterone suppression in opioid users: a systematic review and meta-analysis. Drug Alcohol Depend 2015; 149(5): 1-9.
37. Gladue BA, Clemens LG. Flutamide inhibits testosterone-induced masculine sexual behavior in male and female rats. Endocrinol 1980; 106(6): 1917-22.
38. Nimroozi R, Mastropietro D, Omidian H. Opioid abuse and deterrence: buprenorphine products. J Develop Drugs 2014; 3(117): 2-12.
39. Heidari Z, Mahmoudzadeh S, Kohan F. A quantitative and qualitative study of rat testis following administration of methadone and buprenorphine. Int J High Risk Behav Addict 2012; 1(1): 14-7.
40. Déglon JJ, Martin JL, Imer RL. Methadone patients’ sexual dysfunctions: Clinical and treatment issues. Heroin Add Rel Clin Probl 2004; 6(3): 17-26.
42. Shinderman MS, Maxwell S. Sexual dysfunction associated with methadone maintenance: Treatment with bromocryptine. Heroin Add Rel Clin Probl 2000; 2(1): 9-14.



XML   English Abstract   Print



Creative Commons License
This open access journal is licensed under a Creative Commons Attribution-NonCommercial ۴.۰ International License. CC BY-NC ۴. Design and publishing by Kashan University of Medical Sciences.
Copyright ۲۰۲۳© Feyz Medical Sciences Journal. All rights reserved.
دوره 27، شماره 1 - ( دوماه نامه 1402 ) برگشت به فهرست نسخه ها